药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究*

doi:10.3969/j.issn.1672-5069.2023.04.015

摘要/Abstract

摘要： 目的分析比较药物诱导性自身免疫性肝炎(DI-AIH)、药物性肝损伤(DILI)和自身免疫性肝炎(AIH)患者的临床特征。方法 2017年1月～2021年12月我院收治的22例DI-AIH患者、23例DILI患者和23例AIH患者,给予DI-AIH和AIH患者泼尼松或/和硫唑嘌呤联合治疗,给予DILI患者丁二磺酸腺苷蛋氨酸联合异甘草酸镁注射液治疗,直至肝功能指标正常,随访24个月。结果 DILI组和DI-AIH组明确应用药物百分比分别为82.6%和100.0%,均显著高于AIH组的17.4%(P<0.05),且均以应用中草药为主;三组常见的临床症状为食欲下降、眼黄、腹泻等,且三组临床症状发生率存在显著性差异(DI-AIH、AIH和DILI组分别为81.8%、52.2%和47.8%,P<0.05);DI-AIH组血清ALT、ALP、GGT和总胆汁酸水平分别为331.2(116.4,512.5) U/L、125.4(91.6,164.8) U/L、202.4(98.8,394.1) U/L和23.7(13.1,69.7) μmol/L,显著高于DILI组【分别为198.6(94.3,497.6)U/L、98.9(67.7,168.9)U/L、101.2(49.6,231.4)U/L和7.1(2.7,29.2)μmol/L,P<0.05】或AIH组【分别为86.7(32.4,186.3)U/L、65.8(54.7,109.8)U/L、71.6(61.4,142.5)U/L和11.5(4.1,35.6)μmol/L,P<0.05】,而AIH组血清球蛋白水平为35.6(28.7,41.4) g/L,显著高于DILI组【28.8(21.2,34.5) g/L,P<0.05】或DI-AIH组【30.5(24.6,42.1)g/L,P<0.05】;三组白细胞计数比较差异均无统计学意义(P＞0.05)。结论 DILI和DI-AIH的致病药物主要以中草药应用为主,DI-AIH患者存在一些较特殊的临床特征值得关注,表现为血清酶学水平较高,对免疫抑制和护肝治疗有效。

关键词: 药物诱导性自身免疫性肝炎, 药物性肝损伤, 自身免疫性肝炎, 临床特征

Abstract: Objective The aim of this study was conducted to compare the clinical features of patients with drug-induced autoimmune hepatitis (DI-AIH), autoimmune hepatitis (AIH) and drug-induced liver injury (DILI). Methods 22 patients with DI-AIH, 23 patients with DILI and 23 patients with AIH were encountered in our hospital between January 2017 and December 2021, the patients with AIH and DI-AIH were treated with prednisone and/or azathioprine combination therapy, and those with DILI were dealt with liver-protecting medicines. All patients were followed-up for two years. Results The percentages of definite medicine administered before diagnosis of patients with DILI and DI-AIH were 82.6% and 100.0%, with the alleged Chinese herbal medicine mainly, both significantly higher than 17.4%(P<0.05) in patients with AIH; the incidence of common symptoms, such as anorexia, jaundice and diarrhea in patients with DI-AIH was 81.8%, much higher than 52.2% and 47.8% (P<0.05) in those with AIH or with DILI; serum alanine aminotransaminase, alkaline phosphatase, glutamine transpeptidase and total bile acid levels in patients with DI-AIH were 331.2(116.4, 512.5) U/L, 125.4(91.6, 164.8) U/L, 202.4(98.8, 394.1) U/L and 23.7(13.1, 69.7)μmol/L, all significantly higher than [198.6(94.3, 497.6)U/L, 98.9(67.7, 168.9)U/L, 101.2(49.6, 231.4)U/L and 7.1(2.7, 29.2)μmol/L, respectively, P<0.05] in patients with DILI or [86.7(32.4, 186.3)U/L, 65.8(54.7, 109.8)U/L, 71.6(61.4, 142.5)U/L and 11.5(4.1, 35.6)μmol/L, respectively, P<0.05] in patients with AIH, while serum globulin level in patients with AIH was 35.6(28.7, 41.4) g/L, significantly higher than 28.8(21.2, 34.5) g/L in patients with DILI (P<0.05) or 30.5(24.6, 42.1)g/L in patients with DI-AIH (P<0.05); there were no significant differences as respect to peripheral white blood cell counts among the three groups (P＞0.05). Conclusion The main pathogenic medicines in patients with DILI and DI-AIH are Chinese herbal medicine, and the clinical features of patients with DI-AIH are unique, presenting with highly increased serum biochemical parameters and good prognosis, showing response to immunosuppression and liver-protecting therapy.

Key words: Drug-induced liver injury, Drug-induced autoimmune hepatitis, Autoimmune hepatitis, Clinical features

符馨尹, 林小茹, 郑秀芬, 刘小双. 药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 512-515.

Fu Xinyin, Lin Xiaoru, Zheng Xiufen, et al. Comparison of clinical features of patients with drug-induced autoimmune hepatitis, autoimmune hepatitis and drug-induced liver injury[J]. Journal of Practical Hepatology, 2023, 26(4): 512-515.

参考文献

[1] Brennan PN, Cartlidge P, Manship T,et al. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI). Frontline Gastroenterol, 2021, 13(4): 332-336.
[2] Hoppmann NA, Gray ME, McGuire BM. Drug-induced liver injury in the setting of chronic liver disease. Clin Liver Dis, 2020, 24(1): 89-106.
[3] Chalasani NP, Maddur H, Russo MW,et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2021, 116(5): 878-898.
[4] Tsutsui A, Harada K, Tsuneyama K,et al. Histopathological analysis of autoimmune hepatitis with "acute" presentation: differentiation from drug-induced liver injury. Hepatol Res, 2020, 50(9): 1047-1061.
[5] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 10(1): 1-23.
[6] 中华医学会肝病学分会, 中华医学会消化病学会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 肝脏, 2015, 20(12): 969-982.
[7] Yeong TT, Lim KH, Goubet S, et al. Natural history and outcomes in drug-induced autoimmune hepatitis. Hepatol Res, 2016, 46(3):E79-E88.
[8] Hassoun J, Goossens N, Restellini S, et al. Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: a case-control study. JGH Open, 2023, 7(2): 135-140.
[9] 王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析. 实用肝脏病杂志, 2023, 26(2): 218-221.
[10] de la Torre-Aláez M, Iñarrairaegui M. Drug liver injury induced by olmesartan mediated by autoimmune-like mechanism: a case report. Eur J Case Rep Intern Med, 2020, 7(1): 001407.
[11] Zheng M, Cui S, Zhang W, et al. Graves' disease overlapping with chronic hepatitis B and methimazole-induced liver injury and autoimmune hepatitis: a case report. BMC Gastroenterol, 2022, 22(1): 59.
[12] Mihajlovic M, Vinken M. Mitochondria as the target of hepatotoxicity and drug-induced liver injury: molecular mechanisms and detection methods. Int J Mol Sci, 2022, 23(6): 3315.
[13] Ardila-Suárez OM, Oriz-Benjumea L, Arteta AA, et al. Drug-induced liver injury: relation between the ratio and histopathology. Rev Gastroenterol Mex (Engl Ed), 2023, 88(1): 19-27.
[14] Febres-Aldana CA, Alghamdi S, Krishnamurthy K,et al. Liver fibrosis helps to distinguish autoimmune hepatitis from DILI with autoimmune features: a review of twenty cases. J Clin Transl Hepatol, 2019, 7(1): 21-26.
[15] 刘靓懿, 宿冬远. 药物性肝损伤与自身免疫性肝炎患者临床和肝组织病理学特征比较研究. 实用肝脏病杂志, 2018, 21(3): 463-464.
[16] Weber S, Benesic A, Rotter I,et al. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int, 2019, 39(10): 1906-1917.
[17] Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol, 2018, 31(6): 965-973.
[18] 李变利, 徐丽红. 药物性肝损伤、药物诱导的自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展. 实用肝脏病杂志, 2021, 24(4): 460-463.
[19] Sirbe C, Simu G, Szabo I,et al. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms. Int J Mol Sci, 2021, 22(24): 13578.
[20] Tsutsui A, Harada K, Tsuneyama K, et al. Clinicopathological study of autoimmune hepatitis cases that were difficult to differentiate from drug-induced liver injury. Dig Dis, 2017, 35(6): 506-514.

药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究^*

Comparison of clinical features of patients with drug-induced autoimmune hepatitis, autoimmune hepatitis and drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[2]	张亦瑾, 高学松, 高丽丽, 郝一炜, 段雪飞. 儿童与成人肝豆状核变性患者临床特征和生存分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 520-523.
[3]	王世美, 胡玲, 伍丽萍, 刘丽. 肝硬化并发非创伤性乳糜腹水12例临床特征分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 532-535.
[4]	王凌云, 周永健. 肠道菌群与自身免疫性肝炎研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 317-319.
[5]	朱琳, 陈洋, 杨青, 刘俊启. 超声弹性成像评估自身免疫性肝炎患者肝纤维化分期价值分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 360-363.
[6]	黄慧, 林敏, 曾桂香. 肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*[J]. 实用肝脏病杂志, 2023, 26(3): 364-367.
[7]	郭银燕, 岳枝, 盖晓冬, 冯艳红, 张杰东. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 372-375.
[8]	王俊红, 戴玲, 陈国斌, 杨路平, 周晶. 还原型谷胱甘肽、甘草酸二铵和复方甘草酸苷治疗抗结核药物所致药物性肝损伤患者成本-效益分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 380-383.
[9]	杨开宁, 王梦梦, 陈秀秀, 王占坤, 董紫薇. 不同护肝药物护佑抗痨治疗防治药物性肝损伤发生研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 384-387.
[10]	卫栋萍, 韩黎黎, 凌佳慧, 顾晓琴, 曹永峰. 甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 388-391.
[11]	凌佳慧, 倪美鑫, 韩黎黎, 卫栋萍, 戴轶伟, 陈婷婷. 异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2023, 26(2): 214-217.
[12]	王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 218-221.
[13]	窦婧, 徐强, 王转国, 王宏峰, 乐永红, 王晓波, 付强, 宁忠慧, 胡西百合提, 倪卡, 敬进华, 余虹, 郭峰, 王晓忠. 血清IgG低水平和转氨酶正常的AIH患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 222-225.
[14]	徐菁, 刘坤, 马竹芳. 异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 234-237.
[15]	张彦, 夏文芳, 杨小雷, 王黎, 金进. 甲状腺功能亢进症合并肝损害患者临床特点及影响肝损害发生的危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 238-241.